Progestin-only pills for contraception
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The introduction of a new progestin-only oral contraceptive in Europe has renewed interest in this class of oral contraceptives. Unlike the more widely used combined oral contraceptives containing an estrogen plus progestin, these pills contain only a progestin (progestogen) and are taken without interruption. How these pills compare to others in their class or to combined oral contraceptives is not clear. OBJECTIVES: This review examined randomized controlled trials of progestin-only pills for differences in efficacy, acceptability, and continuation rates. SEARCH METHODS: Through October 2013, we searched the computerized databases MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), POPLINE, and LILACS for studies of progestin-only pills. We also searched for current trials via ClinicalTrials.gov and ICTRP. Previous searches also included EMBASE. SELECTION CRITERIA: We included all randomized controlled trials in any language that included progestin-only pills for contraception. We incorporated any comparison with a progestin-only pill; this could include different doses, other progestin-only pills, combined oral contraceptives, or other contraceptives. DATA COLLECTION AND ANALYSIS: The first author abstracted the data and entered the information into RevMan 5. Another author performed a second, independent data abstraction to verify the initial data entry.We attempted to extract life-table rates (actuarial or continuous) and used the rate difference as the effect measure. Where life-table rates were not published, we used the incidence rate ratio (ratio of Pearl rates). Where only the crude number of events was published, we calculated the Peto odds ratio with 95% confidence interval (CI) using a fixed-effect model. For continuous variables, the mean difference (MD) was computed with 95% CI. Because of disparate exposures, we were not able to combine studies in meta-analysis. MAIN RESULTS: Six trials met the inclusion criteria. We have not found any new studies since the initial review. In the trial comparing the desogestrel versus levonorgestrel progestin-only pill, desogestrel was not associated with a significantly lower risk of accidental pregnancy; the rate ratio was 0.27 (95% CI 0.06 to 1.19). However, the desogestrel progestin-only pill caused more bleeding problems, although this difference was not statistically significant. The trial comparing low-dose mifepristone versus a levonorgestrel progestin-only pill found similar pregnancy rates. In the trial comparing ethynodiol diacetate versus a combined oral contraceptive, irregular cycles occurred in all women assigned to the progestin-only pill (odds ratio 135.96; 95% CI 7.61 to 2421.02). In a trial comparing two progestin-only and two combined oral contraceptives, the progestin-only pill containing levonorgestrel 30 μg had higher efficacy than did the pill containing norethisterone 350 μg. An early trial found megestrol acetate inferior to other progestin-only pills in terms of efficacy. A study of the timing of pill initiation after birth found no important differences, but high losses to follow up undermined the trial. AUTHORS' CONCLUSIONS: Evidence is insufficient to compare progestin-only pills to each other or to combined oral contraceptives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Allocation concealment in randomised trials: defending against deciphering
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07750-4 · Cited by 923
Self-citationHormonal contraception and risk of venous thromboembolism: national follow-up study
Lidegaard, O., Lokkegaard, E., Svendsen, A. L., & Agger, C. (2009) · BMJ · doi:10.1136/bmj.b2890 · Cited by 709
Sample size slippages in randomised trials: exclusions and the lost and wayward.
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07882-0 · Cited by 642
Self-citation
Cited by
Contraception Selection, Effectiveness, and Adverse Effects: A Review
Teal, S., & Edelman, A. (2021) · JAMA · doi:10.1001/jama.2021.21392 · Cited by 336
Progestin-only contraceptives: effects on weight
Lopez, L. M., Ramesh, S., Chen, M., Edelman, A., Otterness, C., Trussell, J., & Helmerhorst, F. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008815.pub4 · Cited by 230
Self-citationMartinelli, I., Lensing, A. W. A., Middeldorp, S., Levi, M., Beyer-Westendorf, J., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Trajanovic, M., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665927 · Cited by 219
An Update on Contraception in Polycystic Ovary Syndrome
Oguz, S. H., & Yildiz, B. O. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.958 · Cited by 76
Morotti, M., Remorgida, V., Venturini, P. L., & Ferrero, S. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.10.029 · Cited by 55
“Surprisingly, although progestins have a lower cardiovascular risk compared to CHC, only a few studies have evaluated these compounds in this high-risk population of patients with MO [21–24] and the use of progestins has not been consistent over time, probably due to the fact that these compounds cause more adverse ef…”
Background
Metadata
- Authors
- Grimes, D. A., Lopez, L. M., O'Brien, P. A., & Raymond, E. G.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-11-13
- Volume
- 2013
- Issue
- 11
- Pages
- CD007541-CD007541
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2148601805
- Cited by
- 101
- References
- 4
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progestin-only pills for contraception. https://app.cochat.ai/papers/10.1002/14651858.cd007541.pub3
- The paper
- Grimes, D. A., Lopez, L. M., O'Brien, P. A., & Raymond, E. G. (2013). Progestin-only pills for contraception. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007541.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.